LitAlert ~~

    • Identifying patients eligible for PARP inhibitor treatment: from NGS-based tests to 3D functional assays.
    • Morice PM, Coquan E, Weiswald LB, Lambert B, Vaur D, Poulain L.
    • Br J Cancer. 2021 Mar 25. doi: 10.1038/s41416-021-01295-z. Epub ahead of print.
    • Commentary, Review
    • Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion.
    • Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, O'Neil BB, Tward JD.
    • JCO Precis Oncol. 2021;5:533. doi: 10.1200/PO.20.00432. Epub 2021 Mar 23.